Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
8:25 MIN
- CIDP
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Incidence of GBS and CIDP Following Influenza Vaccination
25:18 MIN
- CIDP
- GBS
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
IgG Levels and Wear Off Reflect Administration and Outcome
5:51 MIN
- CIDP
- GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
NOW PLAYING
8:25
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...
Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
25:18
Incidence of GBS and CIDP Following Influenza Vaccination
Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.
NOW PLAYING
5:51
IgG Levels and Wear Off Reflect Administration and Outcome
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
Our Experts on CIDP
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
- CIDP
- GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
- CIDP
- GBS
- MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
- CIDP
- MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Slides & Posters about CIDP
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
PDF | 1.4 MB
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
PDF | 250 KB
Back to Top